Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-17

Clinical Trial Update: Emtricitabine/Tenofovir Alafenamide as Salvage ART [Phase 2]

View source ↗

Summary

A Phase 2 trial of emtricitabine/tenofovir alafenamide as salvage ART in HIV was terminated, with results posted in October 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Emtricitabine/Tenofovir Alafenamide (emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV | Phase 2 | Status: TERMINATED | Results posted: 2017-10-17